Drug Trial Radar · NCT07832630
Saruparib in HRDsig+ Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
124
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Nov 1, 2029
Study completion Nov 1, 2030
Sponsor
- Lead sponsor
- Abramson Cancer Center at Penn MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AstraZeneca; Basser Center for BRCA
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to study the effect of saruparib, an experimental PARP inhibitor, on tumors that have an Homologous Recombination Deficiency Signature (HRDsig) positive tumor by the investigational FoundationOne®CDx clinical trial assay.
Conditions
- Malignant Neoplastic Disease (Disorder)
Interventions
SaruparibDrug
Saruparib (AZD5305) 60mg PO daily
FoundationOne®CDxDiagnostic test
Tumors will be tested for positive HRDsig tumor by the investigational FoundationOne®CDx clinical trial assay.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best objective response as determined by RECIST v.1.1Time frame: From baseline through documented disease progression (RECIST v1.1) or death from any cause, whichever occurs first, up to 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.